

OMTO, Volume 22

## **Supplemental information**

### **Silencing ZIC2 abrogates tumorigenesis and anoikis resistance of non-small cell lung cancer cells by inhibiting Src/FAK signaling**

**Aibin Liu, Huayan Xie, Ronggang Li, Liangliang Ren, Baishuang Yang, Longxia Dai, Wenjie Lu, Baoyi Liu, Dong Ren, Xin Zhang, Qiong Chen, Yanming Huang, and Ke Shi**

SUPPLEMENTARY TABLES

**Supplementary table 1.** The basic information of 10 NSCLC patients for ZIC2 RT-qPCR and protein expression analysis.

		Cases (n)	Percentage (%)
Histologic	LUAD <sup>a</sup>	6	60
	LUSC <sup>b</sup>	4	40
Gender	Male	7	70
	Female	3	30
Age	<60	5	50
	≥60	5	50
Grade	G1	0	0
	G2	6	60
	G3	4	40
Stage	Stage I	2	20
	Stage II	5	50
	Stage III	3	30
	Stage IV	0	0

<sup>a</sup>LUAD: Lung adenocarcinoma; <sup>b</sup>LUSC: Lung squamous carcinoma.

**Supplementary table 2.** The basic information of 43 patients with benign human lung disease for ZIC2 in IHC analysis.

		Cases (n)	Percentage (%)
Gender	Male	33	76.7
	Female	10	23.3
Age	<60	34	79.1
	≥60	9	20.9

Type of diseases	Amyloidosis	1	2.3
	Fungal infection	2	4.7
	Hamartoma	3	7.0
	Hyperplasia	19	44.2
	Metaplasia	1	2.3
	Pneumonia	5	11.6
	Pulmonary bulla	5	11.6
	Sclerosing hemangioma	1	2.3
	Tuberculosis	6	14.0

**Supplementary table 3.** The basic information of 261 patients with NSCLC for ZIC2 IHC analysis.

		Cases (n)	Percentage (%)
Histologic	LUAD	168	64.4
	LUSC	93	35.6
Gender	Female	107	41.0
	Male	154	59.0
Age	<60	68	26.1
	≥60	193	73.9
Grade	G1	28	10.7
	G2	128	49.0
	G3	105	40.2
T classification	T1	61	23.4
	T2	137	52.5
	T3	46	17.6
	T4	13	5.0
	NA <sup>a</sup>	4	1.5
N classification	N0	141	54.0

	N1	64	24.5
	N2	44	16.9
	N3	2	0.8
	NA <sup>a</sup>	10	3.8
M classification	M0	243	93.1
	M1	18	6.9
Stage	Stage I	98	37.5
	Stage II	83	31.8
	Stage III	62	23.8
	Stage IV	18	6.9

<sup>a</sup>NA: Not available.

**Supplementary table 4.** A list of primers used in the reactions for clone PCR.

Gene	Sequence (5' - 3')
ZIC2-sh#1-up	CCGGCGGAAGCACATGAAGGTCCATCTCGAGATGGA CCTTCATGTGCTTCCGTTTTTG
ZIC2-sh#1-dn	AATTCAAAAACGGAAGCACATGAAGGTCCATCTCGA GATGGACCTTCATGTGCTTCCG
ZIC2-sh#2-up	CCGGGCAACTGAGCAATCCCAAGAACTCGAGTTCTTG GGATTGCTCAGTTGCTTTTTTG
ZIC2-sh#2-dn	AATTCAAAAAGCAACTGAGCAATCCCAAGAACTCGA GTTCTTGGGATTGCTCAGTTGC
SRC-promoter-up	gccGGTACCgccCAGTTTATCACCGCAAGAGC
SRC-promoter-dn	gccAGATCTGCATCTACTACACGCCAAGC

**Supplementary table 5.** A list of primers used in the reactions for RT-qPCR.

Gene name	Sequence (5' - 3')
ZIC2 forward	GCGCAACTCCACAACCAGTA

	reverse	TGCCGCATATAGCGGAAAAAG
SRC	forward	GTGGACACTCAGGAGAAGAACG
	reverse	TGCTGCTTAATAATCTTGCCCTT
FAK	forward	AGTGGACCAGGAAATTGCTTTG
	reverse	GTGTTTTGGCCTTGACAGAATC
GAPDH	forward	GCACCGTCAAGGCTGAGAAC
	reverse	TGGTGAAGACGCCAGTGGA

**Supplementary table 6.** A list of primers used in the reactions for ChIP assay.

Gene name		Sequence (5' – 3')
SRC-P1	forward	ACCGCAAGAGCTACCATTCA
	reverse	GGGTGGACAAGTCGATCAGC
SRC-P2	forward	CCAGGGAATAGAAGCCTGACC
	reverse	GACTCCCCTCTTACCCCCTG
SRC-P3	forward	TTACTTACTTGGAAGTGTGACTGC
	reverse	TTTCTCAAAGTAGGGGCTGGG
SRC-P4	forward	AATCGTGATTTCTGGGAGAGGC
	reverse	CGGTGACCCGGGAGAGAC
SRC-P5	forward	GCCTGGGAGCCGGAG
	reverse	GCCTGGGAGCCGGAG
SRC-P6	forward	TGAAATCTGAGCCAGTCGGC
	reverse	GGGAGACCAAACGCAGTCT
SRC-P7	forward	CGGCTCAGAAGTTGGCAAAG
	reverse	ACCTGCCACCAATGAGGAAC
SRC-P8	forward	ACTGCCCCTCTAAGTCCCTA
	reverse	ACTAGCCAGCAACCTCACAT